Suraksha Diagnostic Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

Suraksha Diagnostic is trading at Rs 261.4 with near-term consolidation expected , the 2027 target of Rs 260 is approximately 1 percent below the current price. The more compelling case is in the outer years , Rs 300 by 2028 and Rs 395 by 2030 , as the earnings model builds toward that trajectory. Valued at roughly 35x FY26 EPS (₹6.5), with earnings expected to compound near 15% annually before slowing to approximately12%. Street consensus (1-yr) sits at ₹355.

This article breaks down the Suraksha Diagnostic share price target for 2027, 2028, and 2030, the sector-specific drivers behind the analyst model, and the risks that could delay or derail the forecast.

Click Here – Get Free Investment Predictions

Suraksha Diagnostic Company Overview and Share Price Target Summary

Metric	Details
NSE Ticker	SURAKSHA
Sector	Diversified
CMP (14 Aug 2026)	Rs 261.4
Market Cap	Rs 1398 Cr
12M Consensus	₹355 (+36%)
Suraksha Diagnostic Share Price Target 2027	Rs 260 (-1%)
Suraksha Diagnostic Share Price Target 2028	Rs 300 (+15%)
Suraksha Diagnostic Share Price Target 2030	Rs 395 (+51%)
Bull Case 2030	Rs 506
Bear Case 2030	Rs 296

What most investors miss about Suraksha Diagnostic: Published analyst target range of Rs334.5-376.2 found (Jan 2026); DII holding notably high at 23.1%

Valued at roughly 35x FY26 EPS (₹6.5), with earnings expected to compound near 15% annually before slowing to approximately12%. Street consensus (1-yr) sits at ₹355..

Why Analysts Have Set the Suraksha Diagnostic share price target at Rs 260 for 2027

Core Revenue Growth Is Outpacing Sector Benchmarks

This is the clearest reason the analyst model converges on Rs 395 by 2030. Valued at roughly 35x FY26 EPS (₹6.5), with earnings expected to compound near 15% annually before slowing to approximat. Tracking this factor quarterly gives the earliest signal on whether the long-term analyst target stays on course.

Margin Improvement Is Translating Into Earnings Quality

The Suraksha Diagnostic share price target for 2028 , Rs 300 , is built partly on this continuing to hold. If it deteriorates, the timeline for the outer-year forecast extends, not the target itself. Investors should track it with every results cycle.

Balance Sheet Strength Supports Sustained Growth Investment

This underpins Suraksha Diagnostic's growth beyond the 2027 near-term. It is the kind of durable structural factor that keeps analysts positive on the 2030 target even when quarterly numbers disappoint.

Management Has a Track Record of Executing Through Cycles

For the 2028 recovery thesis to work, Suraksha Diagnostic needs to maintain consistency here. One cycle of weakness would not break the long-term case, but two consecutive quarters of deterioration would prompt downgrades.

India's Broader Economic Growth Creates a Structural Tailwind

This is the macro layer that most company-specific screens miss. It amplifies Suraksha Diagnostic's own earnings compounding and is why analysts are more constructive on the 2030 horizon than on 2027.

Suraksha Diagnostic Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown

2027 Target: Rs 260

Rs 260 is the 2027 analyst target, implying near-term consolidation expected , the 2027 target of Rs 260 is approximately 1 percent below the current price. At this level, Suraksha Diagnostic would be trading on forward multiples consistent with the current earnings trajectory. The 2027 milestone is essentially a staging post , confirmed only after two to three quarters of on-track delivery.

2028 Target: Rs 300

Rs 300 is where analysts see Suraksha Diagnostic by 2028, roughly 15 percent above today's price. By FY29, the business should have moved past the near-term consolidation, and the Suraksha Diagnostic share price target for 2028 typically re-rates faster than markets initially expect once the earnings inflection becomes visible.

2030 Target: Rs 395

The long-term case is Rs 395 by 2030 , a potential gain of approximately 51 percent from CMP Rs 261.4, which works out to a 4-year CAGR of roughly 11 percent. By FY31, Suraksha Diagnostic should be operating at a scale and earnings quality that justifies the multiple implied by this target. Please verify all data at NSE and BSE before making any investment decision.

Bull Case and Bear Case for Suraksha Diagnostic by 2030

Bull Case: Rs 506

The bull case lands at Rs 506 by 2030. This requires better-than-expected earnings growth alongside a re-rating of the multiple , both need to land together. Favourable macro conditions, new business wins, or a sector re-rating could drive this scenario without needing extraordinary operational delivery from the company.

Bear Case: Rs 296

The bear case is Rs 296 by 2030 , still above today's price in most scenarios, but a significantly slower path. This applies if earnings miss across FY27 to FY28, competitive pressure intensifies, or a macro slowdown compresses sector multiples before Suraksha Diagnostic can re-rate upward.

Scenario	Target 2030	Return	Key Assumption
Bull Case	Rs 506	+94%	Above-consensus growth; multiple expansion
Base Case	Rs 395	+51%	Base-case CAGR; peer multiples hold
Bear Case	Rs 296	+13%	Earnings miss; macro pressure; multiple contraction

Key Risks to the Suraksha Diagnostic Forecast

Earnings Deceleration

Any quarter where Suraksha Diagnostic's growth falls below expectations is likely to trigger a PE de-rating, not just an EPS miss, compounding the price impact.

Sector Headwinds

Policy changes, commodity cycles, or demand slowdowns specific to Suraksha Diagnostic's sector could reduce visibility on the targets beyond 12 months.

Competitive Disruption

New entrants or pricing aggression from existing competitors can erode the market share assumptions built into the analyst model.

Macro Risks

A broader economic slowdown affecting consumer or corporate spending would compress multiples across the board, regardless of company-specific delivery.

How to Invest in Suraksha Diagnostic

Start by tracking Suraksha Diagnostic's quarterly results against the model assumptions. The Univest Screener gives you live fundamentals, analyst upgrade history, and price alerts on NSE ticker SURAKSHA , the same data points that drive the Suraksha Diagnostic share price target model. Build positions in tranches across the 2027 to 2028 window rather than committing fully now, and consult a SEBI-registered financial advisor before investing.

Track This Stock Live on the Univest Screener

Conclusion

The Suraksha Diagnostic share price target of Rs 260 for 2027, Rs 300 for 2028, and Rs 395 for 2030 reflects the analyst model built on Suraksha Diagnostic's earnings trajectory in the diversified sector. The near-term picture is one of consolidation; the case for patient investors is in the 2028 to 2030 window. Always verify financial data at NSE India and BSE India before making any investment decision.

Download the Univest iOS App or Univest Android App to track Suraksha Diagnostic share price live and get daily stock recommendations.

Frequently Asked Questions on Suraksha Diagnostic Share Price Target 2027 2028 and 2030

What is the Suraksha Diagnostic share price target for 2027?

Ans. The Suraksha Diagnostic share price target for 2027 is Rs 260, which is approximately 1 percent slightly below the current market price of Rs 261.4. This near-term target reflects the analyst consensus as of August 2026. Verify all data at NSE India before investing.

What is the Suraksha Diagnostic share price target for 2030?

Ans. The 2030 analyst target for Suraksha Diagnostic is Rs 395, implying approximately 51 percent potential upside from CMP Rs 261.4. This is the base-case extrapolation from the current earnings growth model. These are analyst estimates and not guaranteed returns.

What is the Suraksha Diagnostic share price target for 2028?

Ans. The Suraksha Diagnostic share price target for 2028 is Rs 300, approximately 15 percent from the current price. By FY29, the business should be past the near-term consolidation phase, which makes the 2028 target more realistically achievable than the 2027 level.

Is Suraksha Diagnostic a good long-term investment?

Ans. Suraksha Diagnostic has a defined earnings growth thesis in the diversified sector, with targets that project meaningful upside by 2030. Whether it suits your portfolio depends on your risk appetite, investment horizon, and current allocation. Speak with a SEBI-registered financial advisor before deciding.

What are the key risks to the Suraksha Diagnostic analyst forecast?

Ans. The most significant risks are earnings deceleration and sector headwinds. Beyond these, broader macro slowdowns and sector-specific headwinds can compress multiples even when the company itself is executing well.

What is the bull case for Suraksha Diagnostic by 2030?

Ans. The bull case target is Rs 506 by 2030. This requires above-consensus earnings growth and a re-rating of the PE multiple , both need to happen together. These are analyst projections, not guaranteed outcomes.

What sector does Suraksha Diagnostic belong to?

Ans. Suraksha Diagnostic operates in the diversified sector. This sector classification influences the peer multiples applied in the analyst target model and the macro factors that most directly affect the company's earnings outlook.

How can I track and invest in Suraksha Diagnostic?

Ans. You can buy Suraksha Diagnostic shares through any SEBI-registered broker using NSE ticker SURAKSHA. The Univest Screener lets you track live fundamentals, set price alerts, and monitor analyst ratings. Always consult a SEBI-registered financial advisor before investing.